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Edited by Gianni CesareniAbstract Activation of angiotensin II (Ang II) type 1 receptor
(AT1R) signaling is reported to play an important role in cardiac
hypertrophy. We previously cloned a novel molecule interacting
with the AT1R, which we named ATRAP (for Ang II type 1
receptor-associated protein). Here, we report that overexpres-
sion of ATRAP signiﬁcantly decreases the number of AT1R
on the surface of cardiomyocytes, and also decreases the degree
of p38 mitogen-activated protein kinase phosphorylation, the
activity of the c-fos promoter and protein synthesis upon Ang
II treatment. These results indicate that ATRAP signiﬁcantly
promotes downregulation of the AT1R and further atten-
uates certain Ang II-mediated hypertrophic responses in
cardiomyocytes.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The renin–angiotensin system exerts a major inﬂuence on
blood pressure along with sodium and the extracellular ﬂuid
balance through the generation of angiotensin II (Ang II), aAbbreviations: Ang II, angiotensin II; ACE, angiotensin-converting
enzyme; AT1R, angiotensin II type 1 receptor; C-terminal, carboxy-
terminal; ATRAP, angiotensin II type 1 receptor-associated protein;
hemagglutinin epitope-tagged ATRAP, HA-ATRAP; FLAG-tagged
mouse AT1R, FLAG-AT1R; PAGE, polyacrylamide gel electropho-
resis; PVDF, polyvinylidene diﬂuoride; Ad.HA-ATRAP, adenoviral
vector expressing hemagglutinin epitope-tagged ATRAP; Ad.LacZ,
adenoviral vector expressing bacterial b-galactosidase; RT, reverse
transcriptase; PCR, polymerase chain reaction; MAPK, mitogen-
activated protein kinase; ERK, extracellular signal-regulated protein
kinase; JNK, c-Jun N-terminal kinase; p38MAPK, p38 mitogen-
activated protein kinase; SRE, serum response element; AT2R,
angiotensin II type 2 receptor
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doi:10.1016/j.febslet.2005.01.068key regulator of cardiovascular homeostasis, and has been
implicated in the pathogenesis of cardiovascular diseases [1].
Cardiac hypertrophy is an adaptive response to both hemody-
namic and non-hemodynamic stimuli, such as hypertension
and myocardial infarction, and is a major risk factor for heart
failure and death [2]. Previous studies have reported that
angiotensin-converting enzyme (ACE) inhibitors both prevent
progression and induce regression of cardiac hypertrophy in
hypertensive patients [3] as well as in experimental animal
models [4,5], and it has been shown that components of the re-
nin–angiotensin system, including angiotensinogen and ACE,
are upregulated in the hypertrophied heart [6,7]. These ﬁndings
suggest that the renin–angiotensin system plays a role in the
development of cardiac hypertrophy leading to heart failure
[8].
Most of the known actions of Ang II are mediated by the
Ang II type 1 receptor (AT1R) [1]. The AT1R is a member
of the superfamily of G protein-coupled receptors and acti-
vates G proteins through regions of the third intracellular loop
and the intracellular carboxy-terminal (C-terminal) tail of the
receptor [9,10]. Previous mutation analysis has revealed that
the C-terminal cytoplasmic end is involved in the control of
AT1R internalization independently of G protein coupling
[11]. Serial deletions of the C-terminal tail lead to a reduction
in internalization and a decrease in the coupling to Gq proteins
[12]. Although the molecular mechanisms behind the control
of these processes are not yet completely understood, they
could well involve direct interaction of the AT1R with diﬀerent
proteins as eﬀectors. This would suggest that the C-terminal
tail of the AT1 receptor plays an important role in linking
receptor-mediated signal transduction to certain speciﬁc bio-
logical response to Ang II, including cardiac hypertrophy.
Employing a yeast two-hybrid screening system, we previ-
ously cloned a novel AT1R-associated protein (ATRAP) that
has three transmembrane domains and speciﬁcally interacts
with the C-terminal cytoplasmic domain of the AT1R. This
protein has been reported to modulate AT1R function in
COS-7 cells, human embryonic kidney 293 cells and vascular
smooth muscle cells [13–15]. In the present study, to clarify
the functional importance of ATRAP in cardiomyocytes, we
examined whether ATRAP is endogenously expressed inblished by Elsevier B.V. All rights reserved.
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Ang II-induced hypertrophic responses of cardiomyocytes.2. Materials and methods
2.1. Cell culture
The immortalized cardiomyocyte cell line H9c2, which expresses
endogenous AT1R, was cultured as described previously [16].
The primary culture of neonatal mouse cardiomyocytes was pre-
pared using the method originally described by Goshima [17] with min-
or modiﬁcations [18,19].2.2. Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis of ATRAP
Total RNA from cardiomyocytes was isolated by the single-step
guanidinium thiocyanate–phenol–chloroform method using ISOGEN
(Nippon Gene). One microgram of total RNA was reverse-transcribed
into cDNA with 1 U/ml reverse transcriptase (Superscript, Invitrogen)
at 37 C for 1 h in standard buﬀer. For the ampliﬁcation of ATRAP
cDNA, the following oligonucleotide primers were designed [from
nucleotide +90 to +333 (a 244-bp fragment)]: sense primer 5 0-
TGCTTGGGGCAACTTCACTATC-30; antisense primer 5 0-
ACGGTGCATGTGGTAGACGAG-3 0 [13]. The reaction was carried
out in a standard reaction mixture and PCR products were analyzed
on a 1.6% agarose gel.
2.3. Production of rabbit anti-ATRAP antibody
A 14-aa synthetic peptide corresponding to amino acids 436–449 of
the C-terminal tail of the mouse ATRAP was produced using standard
solid-phase peptide synthesis techniques. Analysis using the BLAST
computer program showed no signiﬁcant overlap of the immunizing
peptide with any known eukaryotic protein. The peptide was puriﬁed,
conjugated and injected three times intradermally into rabbits at two-
week intervals for production of polyclonal antiserum. The rabbits
developed ELISA titers >1:128 000 prior to exsanguination. Anti-
ATRAP polyclonal antibodies were aﬃnity-puriﬁed and used in the
present study.
2.4. Western blot analysis of ATRAP
Whole cellular extracts from cardiomyocytes were separated on a
12% SDS–polyacrylamide gel (PAGE) and transferred to polyvinyli-
dene diﬂuoride (PVDF) membrane. The membrane was immunoblot-
ted with anti-ATRAP polyclonal antibody or anti-AT1R polyclonal
antibody (Santa Cruz) using the ECL System (Amersham).
2.5. Transient transfection and co-immunoprecipitation
The NH2-terminal hemagglutinin epitope-tagged ATRAP (HA-AT
RAP) [14] in pcDNA3 was transiently co-transfected with a FLAG-
tagged mouse AT1R (FLAG-AT1R) in pcDNA3.1 [11] in cardiac
H9c2 cells according to the PolyFECT protocol (QIAGEN). The ratio
of AT1R to ATRAPDNAwas 1:3. Forty-eight hours after the transfec-
tion, the cells were treated with 100 nM Ang II for 60 min, and crude
membrane fractions prepared from the transfected cells [20] were solubi-
lized in 50 mM Tris–HCl (pH 7.5), 140 mMNaCl, 1 mM CaCl2, 1 mM
phenylmethylsulfonyl ﬂuoride and 1mg of aprotinin/ml (buﬀer A) in the
presence of 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propane-
sulfonic acid. The mixture was gently agitated for 30 min at 4 C and
thereafter centrifuged at 13 000g for 20 min. Cleared supernatants
(100 lg of protein) which contain the plasma membrane and endosome
fractions [21] were diluted 1:10 in buﬀer A and incubated for 2 h at 4 C
with anti-FLAG M1 monoclonal antibody (Sigma) and protein G Se-
pharose (Amersham Biosciences). The beads were then washed in buﬀer
A and the samples were subjected to sodium SDS–PAGE, transferred to
PVDF membrane and probed with an anti-HA polyclonal antibody
(BETHYL Laboratories, Inc.).
2.6. Immunoﬂuorescence
Cardiac H9c2 cells or neonatal mouse cardiomyocytes were co-
transfected with HA-ATRAP and FLAG-AT1R using the method
described above. Forty-eight hours after the transfection, the cellswere treated with 100 nM Ang II for 60 min and then incubated in
fresh medium for 60 min to remove Ang II. The cells were then ﬁxed
and permeabilized with 2% paraformaldehyde and 0.1% Triton
X-100, respectively. HA-ATRAP was detected with rabbit anti-HA
antibody and CY3-labeled anti-rabbit IgG (red label) (Amersham
Pharmacia Biotech). AT1R was detected with mouse anti-FLAG
M1 antibody and Alexa Fluor 488-labeled anti-mouse IgG (green
label) (Molecular Probes), as the secondary antibody. For visualizing
Golgi apparatus and endosomes, we used the Golgi marker vector
(BD Biosciences Clontech) and the endosome marker (BD
Biosciences Clontech) [14].2.7. Preparation of recombinant adenoviral vectors and gene transfer
Adenoviral vectors were prepared using cDNAs coding for HA-
ATRAP (Ad.HA-ATRAP) and bacterial b-galactosidase (Ad.LacZ)
using a commercially available system (Adeno X Expression System,
Clontech). The virus titer was determined with a plaque assay.
The Ad.HA-ATRAP or the Ad.LacZ (5 · 109 pfu/ml) was transfec-
ted into cells. All experiments were performed 48 h after infection.2.8. Cell surface AT1R binding assay
Cardiomyocytes were seeded in 24-well plates the day before the
gene transfer. The Ad.HA-ATRAP or the Ad.LacZ (5 · 109 pfu/ml)
was transfected into cardiac myocytes. Forty-eight hours after the
transfection, the cells were treated with 100 nM Ang II for 60 min
and then incubated in fresh medium for 60 min to remove Ang II.
AT1R binding was measured as described previously [22]. Brieﬂy, after
two washes with phosphate-buﬀered saline (PBS) containing 0.1%
BSA, the cells were incubated for 1 h at 37 C with 0.2 nM 125I-[Sar1,-
Ile8]Ang II in the absence (for the total count) or presence of 1 mM
CV11974. The cells were then washed twice with ice-cold PBS contain-
ing 0.1% BSA and were lysed in 0.5 N NaOH. The radioactivity of the
lysate was measured with a gamma counter. AT1R binding was calcu-
lated as the diﬀerence between the total count and the count from sam-
ples incubated with CV11974.2.9. Determination of mitogen-activated protein kinase (MAPK)
activity
Transfected cardiomyocytes were stimulated as indicated. After
treatment, the cells were extracted with sample buﬀer and appropri-
ately diluted to give equal protein amounts and then used for
SDS–PAGE. Western blot analysis was performed for extracellular
signal-regulated protein kinase (ERK), c-Jun N-terminal kinase
(JNK) and p38 MAPK (p38MAPK) using anti-active ERK1/2, JNK
and p38MAPK polyclonal antibodies (Promega), which recognize only
activated ERK1/2, JNK and p38MAPK that is phosphorylated. To
detect ERK1/2 and p38MAPK, anti-ERK1/2 polyclonal antibody
(Upstate Biochem) and anti-p38MAPK polyclonal antibody (Pro-
mega) were used, respectively. To detect JNKs, a mixture of anti-
JNK1 monoclonal antibody (Pharmingen) and anti-JNK2 monoclonal
antibody (Santa Cruz) was used. The enzyme activity was detected
with the ECL Plus System (Amersham) and luminescence was quanti-
ﬁed with a FUJI Las3000 Luminescence Image Analyzer.2.10. Transcriptional fos promoter assay
Cardiomyocytes were seeded in 24-well plates and transfected with
the c-fos luciferase reporter gene (p2FTL, 1 lg) using SureFECTOR
(B-Bridge International Inc.) according to the manufacturers instruc-
tions. This gene consists of 2 copies of the c-fos 5 0-regulated enhancer
element (357 to 276) containing a serum response element (SRE),
the herpes simplex virus thymidine kinase gene promoter (200–70),
and the luciferase gene [23]. To normalize the transfection eﬃciency,
we employed a dual reporter assay system, in which the pRL-SV40
plasmid (Promega), containing the sea pansy luciferase gene under
the control of the SV40 early enhancer/promoter, was co-transfected
as an internal control. The transfected cells were incubated with ser-
um-free medium for 48 h. Then the cells were treated with Ang II
(100 nM) for 4 h, washed with PBS, and lysed for 15 min with 100
ll of cell lysis buﬀer (Promega Corp) at room temperature. Finally,
20 ll of the cell extract was mixed with 100 ll of a luciferase assay re-
agent (Promega Corp), and luciferase activity was measured as de-
scribed previously [24].
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Cardiomyocytes were incubated with 4 lCi/ml of [3H]phenylalanine
in the culture medium, which contained 0.36 mM unlabeled phenylal-
anine, then stimulated with Ang II for 24 h. Cells were rinsed three
times with cold PBS and treated with 1 ml of 10% (w/v) trichloroacetic
acid for 60 min at 4 C to precipitate proteins. The precipitate was
washed three times with 95% (v/v) ethanol and resuspended in 0.2 M
NaOH. Aliquots were measured in a liquid-scintillation counter [25].
2.12. Statistical analysis
Values are expressed as means ± SE in the text and ﬁgures. The data
were analyzed using ANOVA. If a statistically signiﬁcant eﬀect was
found, a post hoc analysis was performed to detect the diﬀerence be-
tween the groups. Values of P < 0.05 were considered statistically
signiﬁcant.Fig. 1. Demonstration of the endogenous expression of ATRAP at the
mRNA and protein level in cardiomyocytes. (A) RT-PCR analysis of
endogenous ATRAP mRNA in total RNA from mouse heart and
cardiomyocytes. RT-PCR products were visualized by ethidium
bromide staining. A DNA marker (Marker), the positive control
using ATRAP cDNA plasmid (Control), and the negative control
consisting of RT-PCRs lacking reverse transcriptase (RT) are also
shown. (B) Western blot analysis of endogenous ATRAP protein with
anti-ATRAP polyclonal antibody in whole cellular extracts from
mouse heart and cardiomyocytes. The positive control, using in vitro
transcribed/translated ATRAP protein (Control), is also shown.
(C) Subcellular distribution of endogenous ATRAP in cardiomyocytes
based on immunoﬂuorescent detection. Cardiomyocytes were ﬁxed
and co-incubated with rabbit anti-ATRAP antibody. Endogenous
ATRAP was detected using CY3-labeled anti-rabbit IgG (red label) as
the secondary antibody.3. Results
3.1. Cardiomyocytes express ATRAP mRNA and protein
Mouse heart and primary cultured mouse cardiomyocytes
express ATRAP mRNA as detected by RT-PCR (Fig. 1A).
To demonstrate the endogenous expression of ATRAP protein
in cardiomyocytes, we generated aﬃnity-puriﬁed polyclonal
rabbit antibodies directed at the C-terminal region of the mol-
ecule. Western blot analysis revealed ATRAP protein expres-
sion in the mouse heart and cardiomyocytes (Fig. 1B). The
identity of the bands was conﬁrmed from the apparent molec-
ular weight and co-migration with the signal from the in vitro
transcribed and translated ATRAP protein. The reaction mix-
ture from a control empty vector did not exhibit a similar sig-
nal (data not shown).
To verify the intracellular distribution of endogenous
ATRAP in cardiomyocytes, an immunocytochemical analysis
was performed. Immunoﬂuorescence staining of cardiomyo-
cytes revealed a speciﬁc particulate localization of endogenous
ATRAP protein in the perinuclear region of the cell (Fig. 1C).
3.2. ATRAP speciﬁcally interacts with AT1R in cardiac H9c2
cells
To conﬁrm the binding of ATRAP to the full-length AT1R
in cardiac H9c2 cells, a co-immunoprecipitation analysis was
performed. For the immunodetection of ATRAP, the protein
was HA-tagged at the amino terminus, and a polypeptide of
expected size was observed by immunoblotting in transfected
cells (Fig. 2A, 1st lane). ATRAP was co-immunoprecipitated
speciﬁcally from the lysates in association with the AT1R
(Fig. 2A, 4th lane). ATRAP was not detected in control immu-
noprecipitates, including those prepared from the cells express-
ing ATRAP without FLAG-tagged receptors (Fig. 2A, 2nd
lane); this result conﬁrmed the speciﬁcity of this association
in cardiomyocytes.
The co-immunoprecipitation of ATRAP and the AT1R from
cell homogenates suggests co-localization of the two proteins in
the form of a complex in intact cardiac H9c2 cells. The associa-
tion of ATRAP with AT1R was further conﬁrmed by immuno-
ﬂuorescence co-localization analysis. In the cells co-transfected
with the FLAG-AT1R and HA-ATRAP fusion protein and
treated with 100 nMAng II for 0 and 60 min, the AT1R was lo-
cated at the plasmamembrane and in the cytosolic region at time
0 (Fig. 2B, a) and internalized into the perinuclear region at 60
min (Fig. 2B, d). ATRAP was located mainly in the perinuclear
cytosolic region at time 0 (Fig. 2B, b) andwas still detected in the
perinuclear cytosolic region at 60 min (Fig. 2B, e). Superimposi-tion of the images reveals a partial co-localization of FLAG-
AT1R and HA-ATRAP in intracellular compartments in
unstimulated H9c2 cells (Fig. 2B, c), and a substantial Ang II-
induced co-localization of the two proteins in intracellular com-
partments in stimulated H9c2 cells (Fig. 2B, f). Further analysis
to determine these compartments showed that HA-ATRAP co-
localizes with theGolgimarker ECFP-b-1,4-galactosyl transfer-
ase and the vesicle marker of the endocytic pathway GFP-rhoB
(data not shown).
3.3. Adenoviral transfer of recombinant ATRAP decreases
AT1R expression on the cell surface in cardiomyocytes
To elucidate whether ATRAP is involved in the regu-
lation of AT1R function in cardiomyocytes, we used an
Fig. 3. Expression of HA-ATRAP in cardiomyocytes infected with
recombinant adenoviral vectors. (A) Western blot analysis of HA-
ATRAP and AT1R with anti-ATRAP polyclonal antibody and with
anti-AT1R polyclonal antibody in whole cellular extracts from
cardiomyocytes infected with the HA-tagged ATRAP adenoviral
vector (Ad.HA-ATRAP) or the LacZ adenoviral vector (Ad.LacZ).
The control, using whole cellular extracts from uninfected cardiomyo-
cytes (Control), is also shown. (B) Cell surface AT1R binding assay
performed on infected cardiomyocytes as described in Section 2.
\P < 0.05 versus Ad.LacZ, n = 4.
Fig. 2. Demonstration of speciﬁc binding and co-localization of
ATRAP and AT1R. A cardiac H9c2 cells were transiently co-
transfected with HA-tagged ATRAP and FLAG-tagged AT1R. (A)
The plasma membrane and endosome fractions of the cells were
prepared, and receptor complexes were immunoprecipitated by anti-
FLAG antibody. Immunoprecipitates were subjected to SDS–PAGE,
blotted, and probed for the presence of the HA epitope. The positive
control using whole cellular extracts (Extract) is also shown. (B) H9c2
cells were ﬁxed under baseline conditions (a–c) or on stimulation with
100 nM Ang II for 60 min (d–f). Localization of FLAG-AT1R was
determined by using anti-FLAG antibody and green ﬂuorescence
secondary antibody and Localization of HA-ATRAP was detected by
using anti-HA antibody and red ﬂuorescence secondary antibody.
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whole cellular extract conﬁrmed that ATRAP was over-
expressed in cardiomyocytes, which were infected with
Ad.HA-ATRAP (Fig. 3A).
To investigate the possible functional role of a direct interac-
tion between ATRAP and the AT1R, changes in the expres-
sion of AT1R were examined by Western blot analysis using
whole cellular extracts of cardiomyocytes. Adenoviral transfer
of recombinant ATRAP resulted in no apparent changes in the
AT1R protein levels in whole cellular extracts from cardio-
myocytes (Fig. 3A). Next, to determine the changes in AT1R
number on the plasma membrane, cell surface AT1R binding
assay in cardiomyocytes was performed. AT1R-ligand binding
on the surface of unstimulated cardiomyocytes was downregu-
lated by the adenoviral transfer of recombinant ATRAP (Fig.
3B). Scatchard analysis indicated that the decrease in radioli-
gand binding was due to a change in receptor number on the
cardiomyocytes surface (data not shown).
To further elucidate the possible eﬀect of ATRAP on the
internalization of the AT1R, cardiomyocytes infected with
Ad.HA-ATRAP were exposed to 100 nM Ang II for 60 min
and then incubated in fresh medium for 60 min to remove
Ang II. In control cardiomyocytes infected with Ad.LacZ,
the AT1R was localized to the plasma membrane under base-
line conditions, and stimulation with Ang II for 60 min pro-
voked a signiﬁcant internalization of the receptor into the
perinuclear cytoplasm as detected by immunoﬂuorescenceanalysis, which eﬀect was followed by a recycling of the recep-
tor to the plasma membrane after removal of Ang II from the
medium (Fig. 4A, a–c). On the other hand, cardiomyocytes in-
fected with Ad.HA-ATRAP showed a decrease in the number
of AT1R at the plasma membrane and an increase in internal-
ized perinuclear AT1R even under baseline conditions, and the
receptor was still localized mainly in the perinuclear region 60
min after removal of Ang II from the medium (Fig. 4A, d–f).
Furthermore, the results of the radioligand binding assay also
showed that the overexpression of ATRAP signiﬁcantly inhib-
ited the recovery of cell surface AT1R density induced the by
removal of Ang II for 60 min (Fig. 4B).
3.4. ATRAP speciﬁcally inhibits Ang II-induced phosphorylation
of p38MAPK, transcriptional activity of c-fos, and protein
synthesis in cardiomyocytes
We next examined the possible eﬀect of ATRAP on the
downstream eﬀectors of the AT1R signaling pathway in
cardiomyocytes by performing adenoviral transfer of recombi-
nant ATRAP. Treatment with Ang II signiﬁcantly augmented
the phosphorylation of ERK1/2, JNK, and p38MAPK in
cardiomyocytes infected with Ad.LacZ (Fig. 5A–C). Although
the Ang II-induced phosphorylation of ERK1/2 and JNK was
Fig. 4. Promotion of AT1R internalization and inhibition of AT1R
recycling to the plasma membrane by overexpression of HA-ATRAP
in cardiomyocytes. (A) Cardiomyocytes, which were infected with the
HA-tagged ATRAP adenoviral vector (Ad.HA-ATRAP) or the LacZ
adenoviral vector (Ad.LacZ), were transiently co-transfected with
FLAG-tagged AT1R. Neonatal mouse cardiomyocytes were ﬁxed
under baseline conditions (a,d), on stimulation with 100 nM Ang II for
60 min (b,e), or after Ang II removal for 60 min (c,f). Localization of
FLAG-AT1R was determined by using anti-FLAG antibody and
green ﬂuorescence secondary antibody. (B) Cell surface AT1R binding
assay performed on infected cardiomyocytes under baseline conditions
(a,d), on stimulation with 100 nM Ang II for 60 min (b,e), and after
Ang II removal for 60 min (c,f) as described in Section 2. \P < 0.05
versus Ad.LacZ, n = 4.
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of p38MAPK was signiﬁcantly suppressed by overexpression
of HA-ATRAP.
Exposure to Ang II resulted in a signiﬁcant increase in tran-
scriptional activity of the c-fos promoter luciferase reporter
gene in cardiomyocytes infected with Ad.LacZ (Fig. 6A).
However, overexpression of HA-ATRAP prevented the in-
crease in activity of the c-fos promoter by Ang II. Protein syn-
thesis was evaluated through the incorporation of
[3H]phenylalanine into cardiomyocytes (Fig. 6B). Treatment
with Ang II increased the incorporation of [3H]phenylalanine
into cardiomyocytes transfected with adenovirus expressing
LacZ. Interestingly, infection with Ad.HA-ATRAP signiﬁ-
cantly inhibited the Ang II-induced stimulation of [3H]phenyl-
alanine incorporation in cardiomyocytes.4. Discussion
This study reports the following ﬁndings. First, evidence is
provided for the endogenous expression of ATRAP in cardio-
myocytes and its perinuclear localization. Second, ATRAP
was found to promote downregulation of the AT1R in cardio-
myocytes. Third, ATRAP selectively attenuated Ang II-
induced phosphorylation of p38MAPK but not that of
ERK1/2 or JNK. Fourth, ATRAP decreased Ang II-induced
c-fos promoter transcription and protein synthesis in cardio-
myocytes. These results suggest that ATRAP acts as a negative
regulator of hypertrophic responses in cardiomyocytes.
There is evidence that mechanical stress, growth factors,
cytokines, and vasoactive agents induce hypertrophic re-
sponses in cardiomyocytes [26,27]. Although the molecular
mechanisms responsible for cardiomyocyte hypertrophy re-
main to be fully determined, Ang II is reported to be a major
contributor to this process [1]. We have previously reported the
molecular cloning of ATRAP, a novel AT1R C-terminal-
interacting molecule, and the expression of ATRAP mRNA
in the heart [13]. However, it had not been previously clariﬁed
whether ATRAP was actually expressed in cardiomyocytes
and whether it was functionally linked to AT1R signaling (in
cardiomyocytes).
A previous study by our laboratory showed that ATRAP
contains three hydrophobic domains at the amino-terminal
end of the protein and a hydrophilic cytoplasmic carboxyl-
terminal tail, indicating that ATRAP is a transmembrane
protein [14]. Subcellular localization is critical for the action
and regulation of the AT1R [12]. Thus, an important way to
explore cardiac ATRAP function is to determine whether
ATRAP localizes to cellular areas compatible with receptor
activity. In our previous studies using non-cardiac cell lines,
ATRAP was found to be localized both at the plasma mem-
brane and in intracellular vesicular compartments correspond-
ing to the endoplasmic reticulum, Golgi, and endocytic vesicles
on immunoﬂuorescence staining [13,14]. However, the results
of the immunocytochemical analysis in the present study
showed that endogenous and transfected ATRAP is mainly
localized to the perinuclear region in cardiomyocytes, in spite
of the ﬁnding of some degree of localization of AT1R both
at the cell periphery and in the perinuclear cytosole. Interest-
ingly, in contrast to our previous observation of a considerable
co-localization of ATRAP and AT1R at the periphery and in
intracellular compartments in non-cardiac cells [13,14], Ang II
signiﬁcantly facilitated co-localization of the two proteins in a
perinuclear region but not at the cell periphery in cardiomyo-
cytes, as was revealed on immunoﬂuorescence staining. These
results suggest that the association of ATRAP with the
AT1R mainly occurs in perinuclear vesicular membranes such
as the Golgi, and also in endocytic vesicles in cardiomyocytes,
and that ATRAP does not directly interact with the AT1R at
the cell surface. The results of the radioligand binding assay
showed that the number of AT1R at the cell surface decreased
with the overexpression of ATRAP, which also supports the
notion that ATRAP promotes the downregulation of the
AT1R.
Hypertrophic responses to Ang II are mediated directly by
several intracellular signaling cascades through activation of
the AT1R [28]. Because the MAPK family is proposed to play
a critical role in Ang II-induced cardiac hypertrophy and
remodeling [29,30], we examined the involvement of the
Fig. 5. Inhibitory eﬀect of ATRAP on Ang II-induced activation of p38MAPK in cardiomyocytes. Cardiomyocytes were infected with the HA-
tagged ATRAP adenoviral vector (Ad.HA-ATRAP) or the LacZ adenoviral vector (Ad.LacZ), and maintained in serum-free medium for 48 h. Then
the infected cells were stimulated with 100 nM Ang II for various periods of time, as indicated. The cell lysates were subjected to immunoblotting for
phospho- and total ERK1/2 (A), phospho- and total JNK (B), and phospho- and total p38MAPK (C) as described in Section 2. \P < 0.05 versus
time 0, n = 6.
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Adenovirus-mediated overexpression of ATRAP in cardio-
myocytes was accompanied by less Ang II-induced activation
of p38MAPK than in those cells infected with Ad.LacZ. On
the other hand, Ang II-induced phosphorylation of neither
ERK1/2 nor JNK was inhibited by the overexpression of
ATRAP. Earlier, we had speculated that ATRAP broadly
attenuates AT1 receptor-mediated signaling [15]. However,
the present results suggest that the interaction betweenATRAP and the AT1R selectively suppressed the p38MAPK
pathway. This raises the possibility that internalization inhibits
mainly a non-Gq-mediated pathway [31]. The hypertrophic ef-
fect of the MAPK family on cardiomyocytes has not yet been
clariﬁed in detail, and conﬂicting ﬁndings have been reported
on whether activation of ERK1/2 or JNK mediates the speciﬁc
changes in gene expression associated with the pathologic
hypertrophic phenotype [32–34]. However, there is evidence
which has been reported which suggests that p38MAPK is able
Fig. 6. Inhibitory eﬀect of ATRAP on Ang II-induced hypertrophic
responses in cardiomyocytes. (A) Transcriptional fos-luciferase assay.
Cardiomyocytes were infected with the HA-tagged ATRAP adenoviral
vector (Ad.HA-ATRAP) or the LacZ adenoviral vector (Ad.LacZ),
transiently co-transfected with the c-fos promoter luciferase gene, and
treated with 100 nM Ang II for 4 h. The transcriptional activity of the
c-fos promoter was assessed as described in Section 2. \P < 0.05 versus
control, n = 5. (B) [3H]phenylalanine incorporation assay. Mouse
cardiomyocytes were infected with the Ad.HA-ATRAP or the
Ad.LacZ, and treated with 100 nM Ang II for 24 h. [3H]phenylalanine
incorporation was determined as described in Section 2. *P < 0.05
versus control, n = 8.
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hypertrophy [31,33,35–37].
Consistent with the role of p38MAPK activation in the
hypertrophic growth program of cardiomyocytes through
SRE-mediated transcriptional stimulation [35], we observed a
signiﬁcant inhibition of Ang II-stimulated transcriptional acti-
vation of the c-fos promoter, which contains SRE, as well as
Ang II-induced increase in protein synthesis. Taken together,
these results suggest that ATRAP may suppress the AT1R-
mediated cardiomyocyte hypertrophy through an inhibition
of the p38MAPK pathway.
In conclusion, this study provides new and important infor-
mation on the functional signiﬁcance of ATRAP as a negative
regulator in cardiomyocyte hypertrophy. These results suggest
that the activation of ATRAP could be useful to suppress car-
diomyocyte hypertrophy. However, further work is needed to
obtain direct in vivo evidence of the eﬀects of ATRAP on inhi-
bition of cardiac hypertrophy, as well as the speciﬁc mecha-
nisms by which it exerts this eﬀect. Speciﬁc experiments for
this purpose are currently in the planning stage and are ex-
pected to be undertaken at the earliest opportunity.
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